STAAR/$STAA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About STAAR
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
Ticker
$STAA
Sector
Health
Primary listing
Employees
1,157
Headquarters
Website
STAAR Metrics
BasicAdvanced
$1.3B
-
-$1.93
0.62
-
Price and volume
Market cap
$1.3B
Beta
0.62
52-week high
$41.00
52-week low
$13.50
Average daily volume
2.3M
Financial strength
Current ratio
4.943
Quick ratio
3.832
Long term debt to equity
10.523
Total debt to equity
12.039
Profitability
EBITDA (TTM)
-72.989
Gross margin (TTM)
71.70%
Net profit margin (TTM)
-42.45%
Operating margin (TTM)
-36.28%
Effective tax rate (TTM)
2.36%
Revenue per employee (TTM)
$190,000
Management effectiveness
Return on assets (TTM)
-10.71%
Return on equity (TTM)
-25.55%
Valuation
Price to revenue (TTM)
5.923
Price to book
3.95
Price to tangible book (TTM)
4.26
Price to free cash flow (TTM)
-30.395
Free cash flow yield (TTM)
-3.29%
Free cash flow per share (TTM)
-0.887
Growth
Revenue change (TTM)
-32.59%
Earnings per share change (TTM)
-685.67%
3-year revenue growth (CAGR)
-4.98%
10-year revenue growth (CAGR)
12.02%
3-year earnings per share growth (CAGR)
40.97%
10-year earnings per share growth (CAGR)
23.26%
What the Analysts think about STAAR
Analyst ratings (Buy, Hold, Sell) for STAAR stock.
Bulls say / Bears say
STAAR Surgical's recent $30 million share repurchase authorization demonstrates confidence in the company's future prospects and commitment to enhancing shareholder value. (staar.com)
The appointment of Deborah Andrews as Chief Financial Officer and the formation of a Capital Stewardship Committee signal a strategic focus on financial management and growth. (staar.com)
Despite challenges in the Chinese market, STAAR Surgical's ICL sales outside China increased by 13% in fiscal year 2024, indicating strong demand in other regions. (marketchameleon.com)
STAAR Surgical reported a net loss of $20.2 million in fiscal year 2024, a significant decline from the $21.3 million net income in the previous year, primarily due to decreased sales and increased operating expenses. (marketchameleon.com)
The company's gross profit margin declined to 76.3% in fiscal year 2024 from 78.4% in the prior year, reflecting increased cost pressures. (marketchameleon.com)
A significant $27.5 million order from China was not recognized as revenue due to extended payment terms and collectability concerns, highlighting potential risks in the company's largest market. (panabee.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
STAAR Financial Performance
Revenues and expenses
STAAR Earnings Performance
Company profitability
STAAR News
AllArticlesVideos
Shareholder Alert: The Ademi Firm Investigates Whether STAAR Surgical Company Is Obtaining a Fair Price for Its Public Shareholders
Business Wire·21 hours ago
STAAR SURGICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of STAAR Surgical Company - STAA
Business Wire·2 days ago
STAA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of STAAR Surgical Company Is Fair to Shareholders
Business Wire·4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for STAAR stock?
STAAR (STAA) has a market cap of $1.3B as of August 09, 2025.
What is the P/E ratio for STAAR stock?
The price to earnings (P/E) ratio for STAAR (STAA) stock is 0 as of August 09, 2025.
Does STAAR stock pay dividends?
No, STAAR (STAA) stock does not pay dividends to its shareholders as of August 09, 2025.
When is the next STAAR dividend payment date?
STAAR (STAA) stock does not pay dividends to its shareholders.
What is the beta indicator for STAAR?
STAAR (STAA) has a beta rating of 0.62. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.